The CEO of Soleno Therapeutics Anish Bhatnaga disclosed the sale of 93,408 shares of company stock at $35.67 per share on December 11, for a total transaction amount of $3,331,705.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SLNO:
- Soleno Therapeutics assumed with a Buy rating, $40 target at Guggenheim
- Soleno Therapeutics assumed with a Buy at Guggenheim
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Soleno Therapeutics price target raised to $44 from $39 at Oppenheimer
- Eight new option listings and one option delisting on November 8th
